undamentalytics Newsletter
Sign in

Entrada Therapeutics, Inc. balance sheet

At the end of fiscal 2025, Entrada Therapeutics, Inc. had total assets of $377m, total liabilities of $71.2m and shareholders' equity of $306m. It held $90.4m in cash against $0 of debt: net cash of $90.4m.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash and equivalents681019099
Total current assets370440306233
Total assets469526377299
Accounts payable3424
Deferred revenue (current)1321400
Total current liabilities159392421
Total debt0000
Total liabilities227987165
Shareholders' equity242429306233
Net debt (negative = net cash)−68−101−90−99
Shares outstanding33m38m38m39m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: BOLT vs TRDAOCGN vs TRDARANI vs TRDAENSC vs TRDA

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Entrada Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Entrada Therapeutics, Inc.